Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

February 6, 2018

Study Completion Date

July 31, 2021

Conditions
AdenocarcinomaLung Neoplasm
Interventions
DRUG

Pemebit

500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles

DRUG

Cisplatin

75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles

Trial Locations (7)

519-763

Chonnam National University Hwasun Hospital, Hwasun

Unknown

Kyungpook National University Medical Center, Daegu

Chungnam National University Hospital, Daejeon

Kosin University Gospel Hospital, Pusan

Korea university Guro hospital, Seoul

Severance hospital, Seoul

602-739

Pusan National University Hospital, Pusan

All Listed Sponsors
collaborator

Kosin University Gospel Hospital

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Chungnam National University Hospital

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Pusan National University Hospital

OTHER

lead

Chonnam National University Hospital

OTHER

NCT02498860 - Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung | Biotech Hunter | Biotech Hunter